Arcaini Luca, Colombo Nora, Passamonti Francesco, Burcheri Sara, Orlandi Ester, Brusamolino Ercole, Della Porta Matteo, Rumi Elisa, Montanari Francesca, Pascutto Cristiana, Paulli Marco, Lazzarino Mario
Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Viale Golgi 19, 27100 Pavia, Italy.
Leuk Res. 2006 Mar;30(3):277-82. doi: 10.1016/j.leukres.2005.07.006. Epub 2005 Aug 19.
Follicular lymphoma (FL) is generally considered an indolent disorder but a significant subset of patients shows a worse outcome. Aim of this study was to validate the FLIPI score in an independent series of follicular lymphoma patients and to correlate prognostic categories with the period of diagnosis and the use of anthracycline.
We evaluated the clinical characteristics, prognostic stratification, and outcome of 338 patients with follicular lymphoma consecutively diagnosed and followed at our Institution between 1975 and 2002.
The distribution of patients within the prognostic categories of the IPI and FLIPI score, while confirming the indolent outcome of follicular lymphoma, shows that a subset of patients has a worse prognosis. With the IPI score, 62% of patients are in the low risk, 26% in the low-intermediate, and 12% in the high (high-intermediate+high) risk group. With the FLIPI score, 48% of patients are categorized as low risk, 31% as intermediate risk, and 21% as poor risk. With the IPI score, median OS is 17.3 years for the low risk; 6.3 for the intermediate risk, and 5.2 years for the high risk group (p=0.0004). With the FLIPI system, median OS is 15.5 years for the low risk, 8.3 years for the intermediate risk, and 5.2 for the poor risk group (p=0.0002). Prognostic scores were calculated also after dividing patients according to the time of diagnosis: in three periods (before 1987, between 1988 and 1997, and from 1998), as well as in two periods (before and after 1998). In all the periods studied survival of patients classified according to IPI and FLIPI categories was significantly different.
This study shows in an independent series that the FLIPI score is a reproducible prognostic index of clinical utility for the initial assessment of patients with follicular lymphoma.
滤泡性淋巴瘤(FL)通常被认为是一种惰性疾病,但有相当一部分患者预后较差。本研究的目的是在一组独立的滤泡性淋巴瘤患者中验证FLIPI评分,并将预后类别与诊断时间及蒽环类药物的使用情况相关联。
我们评估了1975年至2002年期间在我们机构连续诊断并随访的338例滤泡性淋巴瘤患者的临床特征、预后分层及转归。
IPI和FLIPI评分预后类别中的患者分布情况,在证实滤泡性淋巴瘤惰性转归的同时,显示出一部分患者预后较差。根据IPI评分,62%的患者为低风险,26%为低中风险,12%为高(高中风险+高风险)风险组。根据FLIPI评分,48%的患者被归类为低风险,31%为中风险,21%为不良风险。根据IPI评分,低风险组的中位总生存期为17.3年;中风险组为6.3年,高风险组为5.2年(p=0.0004)。根据FLIPI系统,低风险组的中位总生存期为15.5年,中风险组为8.3年,不良风险组为5.2年(p=0.0002)。还根据诊断时间将患者分为三个时期(1987年之前、1988年至1997年之间以及1998年起)以及两个时期(1998年之前和之后)来计算预后评分。在所有研究时期,根据IPI和FLIPI类别分类的患者生存率存在显著差异。
本研究在一组独立病例中表明,FLIPI评分是一种可重复的、对滤泡性淋巴瘤患者初始评估具有临床实用价值的预后指标。